The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Practice Guidelines for Diseases Caused by Aspergillus
Abstract
Aspergillosis comprises a variety of manifestations of infection. These guidelines are directed to 3 principal entities: invasive aspergillosis, involving several organ systems (particularly pulmonary disease); pulmonary aspergilloma; and allergic bronchopulmonary aspergillosis. The recommendations are distilled in this summary, but the reader is encouraged to review the more extensive discussions in subsequent sections, which show the strength of the recommendations and the quality of the evidence, and the original publications cited in detail. Invasive aspergillosis. Because it is highly lethal in the immunocompromised host, even in the face of therapy, work-up must be prompt and aggressive, and therapy may need to be initiated upon suspicion of the diagnosis, without definitive proof (BIII). Intravenous therapy should be used initially in rapidly progressing disease (BIII). The largest therapeutic experience is with amphotericin B deoxycholate, which should be given at maximum tolerated doses (e.g., 1–1.5 mg/kg/d) and should be continued, despite modest increases in serum creatinine levels (BIII). Lipid formulations of amphotericin are indicated for the patient who has impaired renal function or who develops nephrotoxicity while receiving deoxycholate amphotericin (AII). Oral itraconazole is an alternative for patients who can take oral medication, are likely to be adherent, can be demonstrated (by serum level monitoring) to absorb the drug, and lack the potential for interaction with other drugs (BII). Oral itraconazole is attractive for continuing therapy in the patient who responds to initial iv therapy (CIII). Therapy should be prolonged beyond resolution of disease and reversible underlying predispositions (BIII). Adjunctive therapy (particularly surgery and combination chemotherapy, also immunotherapy), may be useful in certain situations (CIII). Aspergilloma. The optimal treatment strategy for aspergilloma is unknown. Therapy is predominantly directed at preventing life-threatening hemoptysis. Surgical removal of aspergilloma is definitive treatment, but because of significant morbidity and mortality it should be reserved for high-risk patients such as those with episodes of life-threatening hemoptysis, and considered for patients with underlying sarcoidosis, immunocompromised patients, and those with increasing Aspergillus-specific IgG titers (CIII). Surgical candidates would need to have adequate pulmonary function to undergo the operation. Bronchial artery embolization rarely produces a permanent success, but may be useful as a temporizing procedure in patients with life-threatening hemoptysis. Endobronchial and intracavitary instillation of antifungals or oral itraconazole may be useful for this condition. Since the majority of aspergillomas do not cause life-threatening hemoptysis, the morbidity and cost of treatment must be weighed against the clinical benefit. Allergic bronchopulmonary aspergillosis (APBA). Although no well-designed studies have been carried out, the available data support the use of corticosteroids for acute exacerbations of ABPA (AII). Neither the optimal corticosteroid dose nor the duration of therapy has been standardized, but limited data suggest the starting dose should be ∼0.5 mg/kg/d of prednisone. The decision to taper corticosteroids should be made on an individual basis, depending on the clinical course (BIII). The available data suggest that clinical symptoms alone are inadequate to make such decisions, since significant lung damage may occur in asymptomatic patients. Increasing serum IgE levels, new or worsening infiltrate on chest radiograph, and worsening spirometry suggest that corticosteroids should be used (BII). Multiple asthmatic exacerbations in a patient with ABPA suggest that chronic corticosteroid therapy should be used (BIII). Itraconazole appears useful as a corticosteroid sparing agent (BII). Although the frequency of these diseases is on the rise, there is a paucity of randomized comparative trials involving these entities; therefore, the recommendations represent a compromise and consensus among students of these diseases (i.e., the authors). They have synthesized the recommendations from published and personal experience, including case series, open trials, and any comparative trials, as indicated. Aspergillus species are saprophytic molds found worldwide. Diseases caused by Aspergillus species are most commonly caused by Aspergillus fumigatus, with Aspergillus flavus the second most frequently isolated pathogen. Other species reported to cause disease include Aspergillus amstelodami, Aspergillus avenaceus, Aspergillus candidus, Aspergillus carneus, Aspergillus caesiellus, Aspergillus clavatus, Aspergillus glaucus, Aspergillus granulosus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus quadrilineatus, Aspergillus restrictus, Aspergillus sydowi, Aspergillus terreus, Aspergillus ustus, and Aspergillus versicolor. The freq
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NEW YORK STATE JOURNAL OF MEDICINE.
(1901) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1901.02470020041007 · Cited by 1,472
THE SPECTRUM OF THE DISEASE IN 98 PATIENTS
YOUNG, R. C., BENNETT, J. E., VOGEL, C. L., CARBONE, P. P., & DEVITA, V. T. (1970) · Medicine · doi:10.1097/00005792-197003000-00002 · Cited by 972
Self-citationAntifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Self-citationClinical and Immunologic Criteria for the Diagnosis of Allergic Bronchopulmonary Aspergillosis
ROSENBERG, M., PATTERSON, R., MINTZER, R., COOPER, B. J., ROBERTS, M., & HARRIS, K. E. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-4-405 · Cited by 819
Diagnosis of Diseases of the Chest.
(1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-2-292_2 · Cited by 805
Broncho-pulmonary Aspergillosis : A Review and a Report of Eight New Cases
Hinson, K. F. W., Moon, A. J., & Plummer, N. S. (1952) · Thorax · doi:10.1136/thx.7.4.317 · Cited by 790
GERSON, S. L., TALBOT, G. H., HURWITZ, S., STROM, B. L., LUSK, E. J., & CASSILETH, P. A. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-3-345 · Cited by 763
Wald, A., Leisenring, W., van Burik, J., & Bowden, R. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/516480 · Cited by 742
Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J. F., Durand, C., Cuisenier, B., Solary, E., Piard, F., Petrella, T., Bonnin, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.139 · Cited by 706
Therapeutic Outcome in Invasive Aspergillosis
Denning, D. W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.3.608 · Cited by 689
Self-citation
Cited by
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationPractice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Self-citationChronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., Ullmann, A. J., Dimopoulos, G., & Lange, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00583-2015 · Cited by 1,030
Self-citation(2006) · PubMed · Cited by 906
Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790
Self-citationPulmonary aspergillosis: a clinical review
Kousha, M., Tadi, R., & Soubani, A. O. (2011) · European Respiratory Review · doi:10.1183/09059180.00001011 · Cited by 752
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Aspergillus flavus : the major producer of aflatoxin
KLICH, M. A. (2007) · Molecular Plant Pathology · doi:10.1111/j.1364-3703.2007.00436.x · Cited by 677
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Self-citationGould, F. K., Denning, D. W., Elliott, T. S. J., Foweraker, J., Perry, J. D., Prendergast, B. D., Sandoe, J. A. T., Spry, M. J., & Watkin, R. W. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr450 · Cited by 593
Self-citationImaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo Sign
Greene, R. E., Schlamm, H. T., Oestmann, J.-W., Stark, P., Durand, C., Lortholary, O., Wingard, J. R., Herbrecht, R., Ribaud, P., Patterson, T. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/509917 · Cited by 594
Self-citationThe Clinical Spectrum of Pulmonary Aspergillosis
Soubani, A. O., & Chandrasekar, P. H. (2002) · Chest · doi:10.1378/chest.121.6.1988 · Cited by 594
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Invasive aspergillosis in critically ill patients without malignancy
Meersseman, W., Vandecasteele, S. J., Wilmer, A., Verbeken, E., Peetermans, W. E., & Van Wijngaerden, E. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-093oc · Cited by 547
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Invasive fungal infections: a review of epidemiology and management options
Enoch, D. A., Ludlam, H. A., & Brown, N. M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46548-0 · Cited by 501
Allergic bronchopulmonary aspergillosis
Greenberger, P. A. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.130179 · Cited by 476
Current Perspectives on Ophthalmic Mycoses
Thomas, P. A. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.730-797.2003 · Cited by 461
The Impact of Culture Isolation of Aspergillus Species: A Hospital‐Based Survey of Aspergillosis
Perfect, J. R., Cox, G. M., Lee, J. Y., Kauffman, C. A., de Repentigny, L., Chapman, S. W., Morrison, V. A., Pappas, P., Hiemenz, J. W., Stevens, D. A., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/323900 · Cited by 458
Self-citationPagano, L., Caira, M., Nosari, A., Van Lint, M. T., Candoni, A., Offidani, M., Aloisi, T., Irrera, G., Bonini, A., Picardi, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522189 · Cited by 414
Krijgsheld, P., Bleichrodt, R., van Veluw, G. J., Wang, F., Müller, W. H., Dijksterhuis, J., & Wösten, H. A. B. (2013) · Studies in Mycology · doi:10.3114/sim0006 · Cited by 410
The immune response to fungal infections
Shoham, S., & Levitz, S. M. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05397.x · Cited by 392
Aspergillus Galactomannan Detection in the Diagnosis of Invasive Aspergillosis in Cancer Patients
Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., Villard, O., Liu, K.-L., Natarajan-Amé, S., Lutz, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.004 · Cited by 392
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Iwen, P. C., Hinrichs, S. H., & Rupp, M. E. (2002) · Medical Mycology · doi:10.1080/714031073 · Cited by 378
Invasive aspergillosis in the intensive care unit
Meersseman, W., Lagrou, K., Maertens, J., & Wijngaerden, E. V. (2007) · Clinical Infectious Diseases · doi:10.1086/518852 · Cited by 366
Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/505870 · Cited by 361
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Marr, K. A., Patterson, T., & Denning, D. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00035-1 · Cited by 307
Self-citationToll-like Receptor (TLR) Signaling in Response toAspergillus fumigatus
Mambula, S. S., Sau, K., Henneke, P., Golenbock, D. T., & Levitz, S. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201683200 · Cited by 298
Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases
Steinbach, W. J., Benjamin, D. K., Kontoyiannis, D. P., Perfect, J. R., Lutsar, I., Marr, K. A., Lionakis, M. S., Torres, H. A., Jafri, H., & Walsh, T. J. (2004) · Clinical Infectious Diseases · doi:10.1086/421950 · Cited by 293
Self-citationKontoyiannis, D. P., Hachem, R., Lewis, R. E., Rivero, G. A., Torres, H. A., Thornby, J., Champlin, R., Kantarjian, H., Bodey, G. P., & Raad, I. I. (2003) · Cancer · doi:10.1002/cncr.11479 · Cited by 287
Dysbiosis of Gut Fungal Microbiota is Associated With Mucosal Inflammation in Crohn’s Disease
Li, Q., Wang, C., Tang, C., He, Q., Li, N., & Li, J. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000035 · Cited by 279
Pulmonary aspergillosis: a clinical update
Zmeili, O. S., & Soubani, A. O. (2007) · QJM · doi:10.1093/qjmed/hcm035 · Cited by 278
Whole genome comparison of Aspergillus flavus and A. oryzae
Payne, G. A., Nierman, W. C., Wortman, J. R., Pritchard, B. L., Brown, D., Dean, R. A., Bhatnagar, D., Cleveland, T. E., Machida, M., & Yu, J. (2006) · Medical Mycology · doi:10.1080/13693780600835716 · Cited by 268
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Soundappan, K., Garg, M., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 261
Self-citationMousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Walsh, T. J., Petraitis, V., Petraitiene, R., Field‐Ridley, A., Sutton, D., Ghannoum, M., Sein, T., Schaufele, R., Peter, J., Bacher, J., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 253
Self-citationGarnacho-Montero, J., Amaya-Villar, R., Ortiz-Leyba, C., León, C., Álvarez-Lerma, F., Nolla-Salas, J., Iruretagoyena, J. R., & Barcenilla, F. (2005) · Critical Care · doi:10.1186/cc3488 · Cited by 252
Balloy, V., Huerre, M., Latgé, J.-P., & Chignard, M. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.494-503.2005 · Cited by 231
Bonnett, C. R., Cornish, E. J., Harmsen, A. G., & Burritt, J. B. (2006) · Infection and Immunity · doi:10.1128/iai.00909-06 · Cited by 174
Candida auris Genetics and Emergence
Chowdhary, A., Jain, K., & Chauhan, N. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032521-015858 · Cited by 158
Transient Lung-Specific Expression of the Chemokine KC Improves Outcome in Invasive Aspergillosis
Mehrad, B., Wiekowski, M., Morrison, B. E., Chen, S.-C., Coronel, E. C., Manfra, D. J., & Lira, S. A. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-367oc · Cited by 71
Kim, A., Nicolau, D. P., & Kuti, J. L. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01903.x · Cited by 60
Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris
Shivarathri, R., Jenull, S., Chauhan, M., Singh, A., Mazumdar, R., Chowdhary, A., Kuchler, K., & Chauhan, N. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02276-21 · Cited by 41
Survey of aspergillosis in non-neutropenic patients in Swiss teaching hospitals
Garbino, J., Fluckiger, U., Elzi, L., Imhof, A., Bille, J., & Zimmerli, S. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03402.x · Cited by 37
Metadata
- Authors
- Stevens, D. A., Kan, V. L., Judson, M. A., Morrison, V. A., Dummer, S., Denning, D. W., Bennett, J. E., Walsh, T. J., Patterson, T. F., & Pankey, G. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 30
- Issue
- 4
- Pages
- 696-709
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170224877
- Cited by
- 789
- References
- 140
- FWCI
- 39.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.